You're signed outSign in or to get full access.
TCG Crossover Management, LLC
TCG Crossover Management, LLC is a science-driven investment firm based in Palo Alto, California. Founded and led by Managing Partner Chen Yu, the firm specializes in investing in breakthrough and disruptive medicines. As an investment adviser registered with the SEC, it manages both public and private equity investments in the life sciences sector. The firm has approximately 17 employees, primarily investors, and operates with a global perspective while maintaining a core presence in the US and Europe. TCG Crossover Management serves institutional investors and high-net-worth individuals seeking exposure to innovation in healthcare and biotechnology.
Investment Strategy
TCG Crossover Management (TCGX) invests in transformative healthcare and biotechnology companies, with a focus on advancing disruptive and breakthrough medicines. The firm employs a science-driven and crossover investment approach, participating in both private and public markets. Their strategy targets early and late-stage companies with the potential for significant clinical or commercial impact, leveraging deep scientific and industry expertise to identify novel therapeutics and platforms. TCGX seeks to build concentrated portfolios, taking meaningful positions in companies they believe can deliver outsized returns through major advances in medicine.
Latest 13F Filing Activity
TCG Crossover Management, LLC filed their most recent 13F report on Jun 30, 2025 disclosing 37 equity positions with a total 13F market value of $876M. The fund increased holdings in Tango Therapeutics Inc., Cidara Therapeutics Inc., Agios Pharmaceuticals, Inc. among other positions. TCG Crossover Management, LLC reduced exposure to Mineralys Therapeutics Inc., Rapt Therapeutics, Inc., Compass Pathways LTD among others.
Top Holdings
Equity Positions (37)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
C CGON | CG ONCOLOGY INC | 10.90% | $95.4M | 3,670,206 | $42.46 | $26.00 | +$5.5M |
T TNGX | TANGO THERAPEUTICS INC | 6.28% | $55.0M | 10,736,000 | $3.09 | $5.12 | +$40.3M |
C COGT | COGENT BIOSCIENCES INC | 5.71% | $50.0M | 6,964,375 | $9.47 | $7.18 | +$8.3M |
O OCUL | OCULAR THERAPEUTIX INC | 5.64% | $49.4M | 5,319,148 | $8.69 | $9.28 | +$10.4M |
C CDTX | CIDARA THERAPEUTICS INC | 5.60% | $49.0M | 1,005,901 | $26.88 | $48.71 | +$27.3M |
Industry Allocation
Investment Team (5)
| Name | Role | Location | |
|---|---|---|---|
 | Partner | New York, NY , United States | |
 | Head of Trading | Boston, MA , United States | |
 | Managing Partner | CA , United States | |
H Haithem Laaribi | Associate | New York, NY , United States | |
 | Associate | CA , United States |
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more